FDA allows Houston cancer doctor to resume drug trial

Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

The Impact of Right to Try Laws on Medical Access in the United States

Sen. Sanders pushes NIH to rein in drug prices

Shubham Pant MD Anderson Cancer Center

Texas Medical Board sanctions controversial cancer doctor Burzynski

New Drugs for Ovarian Cancer Patients - WSJ

Texas Medical Board sanctions controversial cancer doctor Burzynski

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Oncology

FDA gives controversial doc green light to restart work

New drug targeting high-risk children's cancer is ready for trials - The Institute of Cancer Research, London

World's First Gene Therapy Clinical Trial for Glycogen Storage Disease Approved by FDA - Connecticut Children's

FDA issues warning to controversial Houston cancer doctor

MUSINGS OF A CANCER DOCTOR: War, Malaria, and the Nobel Prize, Article

At the Bedside: New focal therapies at UTHealth Houston make prostate cancer treatment easier on patients - UTHealth News - UTHealth Houston